
Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …

Eli Lilly & Co is to run yet another trial of its Alzheimer’s drug solanezumab, which failed twice in Phase …

Lilly has announced that its Alzheimer’s drug candidate solanezumab has failed its primary endpoints in two key phase III trials. …

Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …

